Expression of ERCC1 and class III β-tubulin in resected non-small cell lung cancer and its correlation with platinum-based adjuvant chemotherapy

International Journal of Biological Markers

Volumn 25, Issue 3, 2010, Pages 141-149

  Zhang, Shucai ^a   Li, Qi ^a   Zhang, Quan ^a   Wang, Jinghui ^a   Zhang, Haiqing ^a   Zhang, Zongde ^a   Wang, Qunhui ^a   Yang, Xinjie ^a   Gu, Yanfei ^a   Zhang, Hui ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Class III tubulin; ERCC1; NSCLC; Prognosis

Indexed keywords

BETA TUBULIN; BETA TUBULIN III; BIOLOGICAL MARKER; CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; PACLITAXEL; PLATINUM; UNCLASSIFIED DRUG; VINORELBINE DITARTRATE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG LESION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIMARY TUMOR; PROTEIN EXPRESSION; RISK FACTOR; SEX DIFFERENCE;

EID: 78650806011     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.1177/172460081002500304     Document Type: Article

References (24)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003; 53: 5-26.
2. NCCN Clinical Practice Guidelines in Oncology V.2.2010.
3. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92-8. (Pubitemid 34438899)
4. Rosell R, Lord RV, Taron M, Reguart N. DNA repair and cisplatin resistance in non-small cell lung cancer. Lung Cancer 2002; 38: 217-27. (Pubitemid 35341796)
5. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006; 355: 983-91.
6. Gan PP, Kavallaris M. Tubulin-targeted drug action: functional significance of class ii and class IVb beta-tubulin in vinca alkaloid sensitivity. Cancer Res 2008; 68: 9817-24.
7. Zheng Z, Chen T, Li X, Haura E, Sharma A, Bepler G. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 2007; 356: 800-8. (Pubitemid 46294612)
8. Katsetos CD, Herman MM, Mörk SJ. Class III beta-tubulin in human development and cancer. Cell Motil Cytoskeleton 2003; 55:77-96.
9. Bhattacharya R, Cabral F. A ubiquitous beta-tubulin disrupts microtubule assembly and inhibits cell proliferation. Mol Biol Cell 2004; 15: 3123-31. (Pubitemid 38850110)
10. Schmidt M, Bastians H. Mitotic drug targets and the development of novel anti-mitotic anticancer drugs. Drug Resist Updat 2007; 10: 162-81.
11. Al Haddad S, Zhang Z, Leygue E, et al. Psoriasin (S100A7) expression and invasive breast cancer. Am J Pathol 1999; 155: 2057-66.
12. Handra-Luca A, Bilal H, Bertrand JC, Fouret P. Extra-cellular signal-regulated ERK-1/ERK-2 pathway activation in human salivary gland mucoepidermoid carcinoma: association to aggressive tumor behavior and tumor cell proliferation. Am J Pathol 2003; 163: 957-67.
13. Sève P, Isaac S, Tredan O, et al. Expression of class III β-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clin Cancer Res 2005; 11: 5481-6.
14. El-Kareh AW, Labes RE, Secomb TW. Cell cycle checkpoint models for cellular pharmacology of paclitaxel and platinum drugs. AAPS J 2008; 10: 15-34.
15. Okuda K, Sasaki H, Dumontet C, et al. Expression of excision repair cross-complementation group 1 and class III beta-tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer. Lung Cancer 2008; 62: 105-12.
16. Azuma K, Sasada T, Kawahara A, et al. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel. Lung Cancer 2009; 64: 326-33.
17. Friedberg EC. How nucleotide excision repair protects against cancer. Nat Rev Cancer 2001; 1: 22-33.
18. Cheng L, Spitz MR, Hong WK, Wei Q. Reduced expression levels of nucleotide excision repair genes in lung cancer: a case-control analysis. Carcinogenesis 2000; 21:1527-30.
19. Cobo M, Isla D, Massuti B, et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol 2007; 25: 2747-54.
20. Wang HM, Feng JX, Zhang XY, et al. Prognostic analysis of ERCC1, RRM1 and p53 expressions in postoperative stage I-II lung cancer. Chin J Lung Cancer 2009: 12: 387-95.
21. Li XQ, Li J, Shi SB, Chen P, Yu LC, Bao QL. Expression of MRP1, BCRP, LRP and ERCC1 as prognostic factors in non-small cell lung cancer patients receiving postoperative cisplatin-based chemotherapy. Int J Biol Markers 2009; 24: 230-7.
22. Sève P, Lai R, Ding K, et al. Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10. Clin Cancer Res 2007; 13: 994-9.
23. Sève P, Mackey J, Isaac S, et al. Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Ther 2005; 4: 2001-7. (Pubitemid 43056983)
24. Simon GR, Sharma S, Cantor A, Smith P, Bepler G.. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest 2005; 127: 978-83.